Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia-Reference-Cited by-同舟云学术

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Published:2003-04 Issue:2 Volume:30 Page:116-120
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Kyle Robert A.,Treon Steven P.,Alexanian Raymond,Barlogie Bart,Björkholm Magnus,Dhodapkar Madhav,Lister T.Andrew,Merlini Giampaolo,Morel Pierre,Stone Marvin,Branagan Andrew R.,Leblond Véronique

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference17 articles.

1. To treat or not to treat, this is the real question;Waldenstrom;Leuk Res,1991

2. Waldenström's macroglobulinemia: Clinical features, complications, and management;Dimopoulos;J Clin Oncol,2000

3. Waldenström's macroglobulinaemia: Presenting features and outcome in a series with 217 cases;Garcia-Sanz;Br J Haematol,2001

4. Prognostic factors in Waldenström's macroglobulinemia: A report of 167 cases;Facon;J Clin Oncol,1993

5. Waldenström's macroglobulinaemia;Dimopoulos;Blood,1994

Cited by 280 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Management of Waldenstrom Macroglobulinemia;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia;Journal of Clinical Oncology;2024-07-20

3. Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems.;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29

4. The landscape of rare genetic variants in familial Waldenström macroglobulinemia;Blood Neoplasia;2024-06

5. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom’s macroglobulinemia;International Journal of Hematology;2024-04-10